RECENT FUNDING
  1. Recent Funding
  2. Companies
  3. CatalYm

CatalYm

CatalYm develops immune therapies for solid tumors.

Latest funding

$150M Series B+ ·

Led by Bioqube Ventures · Source: fundraisingfox.com

Total raised: $259.04M across 3 sourced rounds

All 3 rounds ↓
Website: catalym.com.
LinkedIn: linkedin.com.
Category: Health and bio.
Sectors: Biotechnology, Health Care, Medical, Therapeutics.
Stage: Series B+.
Based in: Martinsried, Germany.
Total raised: $259.04M in 3 sourced rounds.
Last round: Jul 16, 2024 · 853 days ago.
Headcount: 11–50 employees.
On Recent Funding since: Oct 1, 2026.

Signals

Website registeredJul 18, 2016 (10 years old)
About CatalYm

It identifies GDF-15 as a key cancer therapy resistance mechanism and aims to neutralize it. CatalYm's lead antibody, Visugromab, is in clinical trials for patients with relapsed and refractory metastatic solid tumors. The company focuses on advancing its therapies through clinical development.

TIMELINE · MONEY RAISED

CatalYm | 2197 days on the record

Raised $259M in 3 sourced rounds
$65M$130M$194M$259MDECOCTAUGJUNAPRFEBDECOCT$259M$59.04M Series B+ · Nov 10, 2020$59.04M B+ · NOV '20$50M Series B+ · Nov 22, 2022$50M B+ · NOV '22$150M Series B+ · Jul 16, 2024$150M B+ · JUL '24

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

DateRoundAmountLeadSource
Series B+$150MBBioqube Venturesfundraisingfox.com
Series B+$50MBBrandon Capitalendpts.com
Series B+$59.04MVVesalius Biocapital Partnersapnews.com

Timeline

  1. Website created

Founders and team

Investors

Companies like CatalYm

Other companies backed by Bioqube Ventures

Bioqube Ventures portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/catalym (get a free API key).

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy